SY vs DBVT vs NVAX vs MTCH vs SNY

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -2. 1% for So-Young International Inc. (SY). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate So-Young International Inc. (SY) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Sanofi at 18. 1x. On forward P/E, Sanofi is actually cheaper at 10. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Sanofi (SNY) delivered a total return of +2.

5%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: MTCH returned +195. 5% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sanofi (SNY) is the lower-risk stock at 0.

51β versus Novavax, Inc. 's 2. 11β — meaning NVAX is approximately 310% more volatile than SNY relative to the S&P 500. On balance sheet safety, So-Young International Inc. (SY) carries a lower debt/equity ratio of 12% versus 30% for Sanofi — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -2. 1% for So-Young International Inc. (SY). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -28. 4% for So-Young International Inc.. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -40. 2% for So-Young International Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -42. 6% for SY. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sanofi (SNY) trades at 10.

3x forward P/E versus 13. 5x for Match Group, Inc. — 3. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, SNY (5.

1% yield), MTCH (2. 0% yield), SY (1. 6% yield) pay a dividend. DBVT, NVAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Sanofi (SNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51), 5. 1% yield). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SNY: +57. 1%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SY (Healthcare) and DBVT (Healthcare) and NVAX (Healthcare) and MTCH (Communication Services) and SNY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SY is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; NVAX is a small-cap high-growth stock; MTCH is a small-cap deep-value stock; SNY is a mid-cap income-oriented stock. SY, MTCH, SNY pay a dividend while DBVT, NVAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.